{"id":"W4411022712","doi":"10.1097/qai.0000000000003699","title":"Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced People Living With Multidrug-Resistant HIV-1: A Phase 3, Multicenter, Expanded Access Study","year":2025,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Medicine; Regimen; Compassionate Use; Adverse effect; Viral load; Expanded access; Internal medicine; Multiple drug resistance; Human immunodeficiency virus (HIV); Phases of clinical research; Drug resistance; Clinical trial; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002864467,0.001022896,0.001381878,0.0004238559,0.0004928762,0.0008767353,0.0006846873,0.0008585627,0.002166845],"category_scores_gemma":[0.00149769,0.0005732556,0.001035986,0.0004419285,0.0006366507,0.001156878,0.0004071642,0.002280291,0.0004616177],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000533879,"about_ca_system_score_gemma":0.001060442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001005534,"about_ca_topic_score_gemma":0.001552077,"domain_scores_codex":[0.9990995,0.0005227831,0.00004881803,0.0000971698,0.0001072967,0.0001243902],"domain_scores_gemma":[0.9988531,0.0002245243,0.0003093038,0.00009634526,0.00007744165,0.0004393033],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.692822,0.1769443,0.02290702,0.0007143166,0.00156954,0.0002820665,0.0008718061,0.0008037019,0.02065741,0.0001364738,0.00164983,0.08064163],"study_design_scores_gemma":[0.4369414,0.510102,0.04815296,0.00006192167,0.0007065693,0.0002660448,0.0001495503,0.001070989,0.001362721,0.0001111092,0.001039444,0.00003528035],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982587,0.0004581254,0.0001132173,0.00008679449,0.00002014618,0.0005824448,0.0001442403,0.000016086,0.000320332],"genre_scores_gemma":[0.9963738,0.0006505998,0.0007775533,0.0004097137,0.0001198614,0.0009494222,0.0003126625,0.00001029348,0.0003959982],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002864467,"threshold_uncertainty_score":0.01514894,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03046205143001382,"score_gpt":0.3479751282784997,"score_spread":0.3175130768484859,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}